LANDMARK STUDY SHOWS PATIENTS TAKING A REGIMEN BASED ON PFIZER扴 NORVASC^{?/SUP> (amlodipine besylate) HAVE A REDUCED RISK OF DEVELOPING DIABETES}

New results from ASCOT show that patients receiving a Norvasc-based regimen had a 34% lower risk of developing new-onset diabetes compared with those taking a beta blocker based regimen 

[insert city], September 6 ?Results from